Johnson & Johnson (JNJ) Com Stk USD 1 (CDI)

Sell:$218.66Buy:$218.70Price decreased$0.91 (0.41%)

Dow Jones:Price decreased0.17%
Market closed |
Prices delayed by at least 15 minutes
Sell:$218.66
Buy:$218.70
Change:Price decreased$0.91 (0.41%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$218.66
Buy:$218.70
Change:Price decreased$0.91 (0.41%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Key people

Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
James Swanson
Executive Vice President, Chief Information Officer
Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Elizabeth Forminard
Executive Vice President, Chief Legal Officer
John C. Reed
Executive Vice President - Innovative Medicine, Research and Development
Tim Schmid
Executive Vice President, Worldwide Chairman of MedTech
Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Marillyn A. Hewson
Lead Independent Director
Daniel E. Pinto
Director
Mary Catherine Beckerle
Independent Director
Jennifer A. Doudna
Independent Director
Paula A. Johnson
Independent Director
Click to see more

Key facts

  • Shares in issue
    3.12bn
  • EPIC
    JNJ
  • ISIN
    US4781601046
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $526.82bn
  • Employees
    138,100
  • Exchange
    New York Stock Exchange
  • Index
    Dow Industry, S&P 500, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.